NCT02814968 2022-04-14PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving EnzalutamideThe European Uro-Oncology GroupPhase 2 Completed66 enrolled
NCT02815033 2022-04-14Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving EnzalutamideThe European Uro-Oncology GroupPhase 2 Completed66 enrolled
NCT02407054 2021-05-11A Study of Enzalutamide and LY3023414 in Men With Prostate CancerEli Lilly and CompanyPhase 2 Completed142 enrolled 16 charts